SCHEMBL2117209

SCHEMBL2117209

CC(=O)N(Cc1ccccc1)Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.62
ALDH1A1 P00352 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CHRM2 P08172 1/20 0.54
CHRM4 P08173 1/20 0.54
CHRM5 P08912 1/20 0.54
CHRM1 P11229 1/20 0.54
CHRM3 P20309 1/20 0.54
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
CA12 O43570 1/20 0.53
CA9 Q16790 1/20 0.53
TSHR P16473 2/20 0.53
TSPO P30536 1/20 0.53
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.51
CRHBP P24387 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3836681 0.90 LMNA (0.72) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL1059560 0.90 LMNA (0.56) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL11378089 0.88 LMNA (0.55) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL10759603 0.87 CTSS (0.51) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL678725 0.86 L3MBTL1 (0.54) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL3662061 0.86 LMNA (0.58) LMNAALDH1A1MEN1KMT2ACHRM2
SCHEMBL2186353 0.86 RCE1 (0.56) LMNAALDH1A1MEN1KMT2ANPC1
SCHEMBL13900616 0.85 LMNA (0.51) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL9903334 0.85 CARM1 (0.55) LMNAALDH1A1NPSR1MEN1KMT2A
SCHEMBL9324870 0.85 MEN1 (0.57) LMNAALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110156692-A The method that palladium acetate catalyzes and synthesizes 5- acetyl group -3- chlorine iminodibenzyl 安徽瑞赛生化科技有限公司 2019-08-23 CN claimed
CN-104876870-B A kind of synthetic method of clomipramine hydrochloride intermediate 江苏同禾药业有限公司 2017-10-10 CN claimed
CN-104876870-A Synthetic method of clomipramine hydrochloride intermediate JIANGSU TOHOPE PHARMACEUTICAL CO LTD 2015-09-02 CN claimed
EP-1129084-B1 THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS GLAXO GROUP LTD (GB) 2005-03-02 EP claimed
EP-1129084-A2 PPAR GAMMA LIGANDS GLAXO GROUP LIMITED (GB) 2001-09-05 EP claimed
WO-2000027832-A2 THIAZOLE DERIVATIVES AS PPAR GAMMA LIGANDS GLAXO GROUP LIMITED (GB) 2000-05-18 WO claimed
US-5859190-A SOLID PHASE SYNTHESIS TO FORM A PROTECTED DIPEPTIDE FOLLOWED BY REACTING WITH 1,1'-THIOCARBONYLDIIMIDAZOLE TO EFFECT RING FORMATION; EFFICIENCY; ANTICONVULSANT,-ARRHYTHMIC AND DIABETIC AGENTS; HERBICIDES AND FUNGICIDES TREGA BIOSCIENCES, INC. (US) 1999-01-12 US claimed
WO-1998033776-A1 COMBINATORIAL LIBRARIES OF HYDANTOIN AND THIOHYDANTOIN DERIVATIVES, METHODS OF MAKING THE LIBRARIES AND COMPOUNDS THEREIN TREGA BIOSCIENCES, INC. (US) 1998-08-06 WO claimed
EP-0687263-B1 PROCESS FOR PREPARING (TRANS)-6- [2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER LAMBERT CO (US) 1997-07-30 EP claimed
EP-0687263-A1 NOVEL PROCESS FOR -i(TRANS)-6- 2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER LAMBERT CO (US) 1995-12-20 EP claimed
WO-1994020492-A1 NOVEL PROCESS FOR TRANS-6-[2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER-LAMBERT COMPANY (US) 1994-09-15 WO claimed
CN-114031477-B Method for reducing amide compounds into amine compounds by cobalt catalysis 浙江工业大学 2023-12-05 CN disclosed
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. (US) 2023-10-19 US disclosed
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. (US) 2023-10-19 US disclosed
WO-2023116569-A1 COMPOSITION COMPRISING A LIPASE AND A BOOSTER NOVOZYMES A/S (DK) 2023-06-29 WO disclosed
WO-1994020492-A1 NOVEL PROCESS FOR TRANS-6-[2-(SUBSTITUTED-PYRROL-1-YL)ALKYL]PYRAN-2-ONE INHIBITORS OF CHOLESTEROL SYNTHESIS WARNER-LAMBERT COMPANY (US) 1994-09-15 WO disclosed
EP-0613879-A1 PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT TSUMURA & CO. (JP) 1994-09-07 EP disclosed
US-5328884-A Salicylic acid salt,and amide or sulfonamide as developer KANZAKI PAPER MANUFACTURING CO., LTD. (JP) 1994-07-12 US disclosed
US-5250108-A Mixture of salicylic acid salt, amide and sulfonamide compounds KANZAKI PAPER MANUFACTURING CO. LTD. (JP) 1993-10-05 US disclosed
US-4920091-A CONTAINING SALICYLIC ACID DERIVATIVE AS ELECTRON ACCEPTING COLOR DEVELOPER; STABLE IMAGES FUJI PHOTO FILM CO., LTD. (JP) 1990-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331751-A1 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES NUDT1, PNP, ATIC LMNA 4604/4885ALDH1A1 946/4885NPSR1 755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.